Sector News

Century Therapeutics changes leadership as CEO steps down

April 15, 2023
Life sciences

Century is one of several companies developing “allogeneic” cell therapies, which involve cells from donors and are meant to be more convenient than personalized, “autologous” CAR-T counterparts. The company was launched by Versant Ventures in 2019 with $250 million in funding — a sizable round that included the financial support of Bayer — and added another $211 million in an initial public offering two years later.

But Century has been swept up in the biotech sector’s downturn since then, a pullback that’s hit cell therapy developers particularly hard. The company has also dealt with growing skepticism around allogeneic treatments, which have struggled to match the high bar set by CAR-T therapies and are dealing with increased competition from bispecific antibodies. Century has lost more than 80% of its value since its IPO and, in January, laid off 25% of its staff and restructured its pipeline. Others such as Celularity and Fate Therapeutics have restructured in the last few months as well.

Century began a Phase 1 trial of a prospective lymphoma treatment in February. The study will test the potential of a repeat dosing regimen, one strategy allogeneic cell therapy developers are evaluating to boost the durability. That effort will, for now, be led by Russotti, a former cell therapy executive with Celgene. READ MORE

By Delilah Alvarado


comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach